Pronova BioPharma ASA (OSE: PRON) (“Pronova BioPharma” or the “Company”) today announces that it has entered into a worldwide licence and development agreement with FMC Corporation (NYSE: FMC) (“FMC”) to develop products using a novel capsule technology.
